$AbbVie (ABBV.US)$ On Oct. 7, AbbVie said top-line results s...

$AbbVie(ABBV.US)$ On Oct. 7, AbbVie said top-line results showed Rinvoq (Upadacitinib) met the primary endpoint of two studies that were part of a Phase III SELect-Axis 2 trial testing its oral JAK inhibitor in patients with axial spinal arthritis. Rinvoq is already approved for rheumatoid arthritis in the United States and Europe, and the company has been looking to add more indications to its label and recently filed for use in ulcerative colitis, although the FDA has delayed some decisions as it reviews some safety issues involving JAK inhibitors.